Visacor

Riik: Uus-Meremaa

keel: inglise

Allikas: Medsafe (Medicines Safety Authority)

Toimeaine:

Rosuvastatin calcium 5.2mg equivalent to 5 mg rosuvastatin;  ;  ;  

Saadav alates:

AstraZeneca Limited

INN (Rahvusvaheline Nimetus):

Rosuvastatin calcium 5.2 mg (= 5 mg rosuvastatin)

Annus:

5 mg

Ravimvorm:

Film coated tablet

Koostis:

Active: Rosuvastatin calcium 5.2mg equivalent to 5 mg rosuvastatin       Excipient: Calcium phosphate Crospovidone Hypromellose as Opadry Yellow Iron oxide yellow as Opadry Yellow Lactose monohydrate as Opadry Yellow   Magnesium stearate Microcrystalline cellulose Titanium dioxide as Opadry Yellow Triacetin as Opadry Yellow

Ühikuid pakis:

Blister pack, Al/Al foil, 7 tablets

Klass:

Prescription

Retsepti tüüp:

Prescription

Valmistatud:

Lonza AG

Näidustused:

VISACOR is indicated to: - Reduce elevated LDL-C, Total Cholesterol, triglycerides and to increase HDLcholesterol in patients with primary hypercholesterolemia (heterozygous familial and non familial) and mixed dyslipidaemia (Fredrickson Types IIa and IIb). - Treat isolated hypertriglyceridaemia (Fredrickson Type IV hyperlipidaemia). Reduce Total Cholesterol and LDL-C in patients with homozygous familial hypercholesterolemia, as an adjunct to diet and other lipid lowering treatments (eg. LDL apheresis) or alone if such treatments are unavailable.

Toote kokkuvõte:

Package - Contents - Shelf Life: Blister pack, Al/Al foil - 7 tablets - 36 months from date of manufacture stored at or below 30°C - Blister pack, Al/Al foil - 30 tablets - 36 months from date of manufacture stored at or below 30°C

Loa andmise kuupäev:

2009-07-31